View Older Stories View More Recent Stories

Mar 3, 2025 01:11AM AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Feb 28, 2025 02:00AM AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
Feb 26, 2025 08:00AM AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
Feb 14, 2025 08:50AM AbbVie (ABBV) appoints CEO as Chairman of board
Feb 14, 2025 07:40AM AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Feb 13, 2025 11:57AM AbbVie Declares Quarterly Dividend
Feb 12, 2025 08:44AM AbbVie's Allergan Aesthetics set to launch three new training centers in U.S.
Feb 12, 2025 08:30AM Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Feb 12, 2025 07:31AM AbbVie (ABBV) and Xilio Therapeutics (XLO) Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Feb 12, 2025 07:30AM AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Feb 7, 2025 01:28PM AbbVie (ABBV) Announces FDA Approval of EMBLAVEO
Feb 7, 2025 01:27PM U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
Feb 6, 2025 08:05AM Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Feb 5, 2025 09:00AM Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
Jan 31, 2025 07:36AM AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Jan 24, 2025 04:00AM Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
Jan 23, 2025 09:17AM AbbVie (ABBV) Completes Acquisition of Nimble Therapeutics
Jan 23, 2025 09:16AM AbbVie Completes Acquisition of Nimble Therapeutics
Jan 23, 2025 09:00AM AbbVie (ABBV) and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Jan 23, 2025 09:00AM AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Jan 13, 2025 09:05AM Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Jan 13, 2025 09:00AM AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Jan 13, 2025 08:31AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 13, 2025 08:31AM AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 9, 2025 08:00AM AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 3, 2025 08:00AM AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Dec 26, 2024 09:00AM Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Dec 13, 2024 09:15AM AbbVie (ABBV) to Acquire Nimble Therapeutics
Dec 13, 2024 09:15AM AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Dec 11, 2024 09:15AM AbbVie (ABBV) Completes Acquisition of Aliada Therapeutics
Dec 11, 2024 09:15AM AbbVie Completes Acquisition of Aliada Therapeutics
Dec 9, 2024 12:02PM AbbVie (ABBV): Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-
Dec 9, 2024 12:00PM Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Dec 9, 2024 08:02AM AbbVie (ABBV) Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec 9, 2024 08:00AM AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec 8, 2024 03:00PM AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
Dec 7, 2024 07:00PM Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Nov 25, 2024 08:00AM AbbVie to Present at Citi's 2024 Global Healthcare Conference
Nov 18, 2024 09:00AM Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov 18, 2024 01:00AM AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Nov 14, 2024 08:15AM AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
Nov 11, 2024 08:35AM AbbVie (ABBV) Phase 2 Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint
Nov 11, 2024 08:30AM AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
Nov 7, 2024 08:00AM Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
Nov 5, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
Oct 31, 2024 08:02AM AbbVie (ABBV), EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Oct 31, 2024 08:00AM AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Oct 30, 2024 07:38AM AbbVie Reports Third-Quarter 2024 Financial Results
Oct 29, 2024 08:00AM SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
Oct 28, 2024 08:01AM AbbVie (ABBV) Acquires Aliada Therapeutics
View More Recent Stories View Older Stories